Feed BCDA
Summary
35 / 100 · Bulios Score
Valuation 36Growth 0Profitability -Quality 0Debt 100Stability 60
What speaks for it
- It holds more cash than debt: $4.12M against $293.0K.
- The price moves less than the market (beta 0.49).
What to watch
- It passes only 1 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedIs it growing?
It is shrinkingRevenue (USD)
2021202220232024202520262027
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $7.34M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $4.12M
Debt $293.0K
Free cash flow over 12 months -$7.57M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 4
- Hold 1
- Sell 0
No analyst has published a price target.
80% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2023By product
- Collaboration Agreement 100%
By region
The company reports no revenue by region.
Collaboration Agreement brings in 100% of revenue.
Segments in detail